Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Issue 6 (17th December 2015)

• Record Type: Journal Article
• Authors: Bakhsh, Salwa; Kinloch, Mary; Hoang, Lien N; Soslow, Robert A; Köbel, Martin; Lee, Cheng‐Han; McAlpine, Jessica N; McConechy, Melissa K; Gilks, C Blake
• Is Part Of: Histopathology. Volume 68:Issue 6(2016)
• Page Start: 916
• Page End: 924
• Publication Date: 2015-12-17
• Subjects: endometrial carcinoma -- mutations -- POLE -- TCGA; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.12878
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: To characterize the histomorphological features of endometrial carcinomas (ECs) harbouring polymerase ε ( POLE ) mutations. Methods and results: Forty‐three ECs with POLE mutations were compared with a cohort of 202 ECs. Most POLE ‐mutated ECs were endometrioid [34/43 (79%)]; the remaining tumours were mixed [6/43 (14%)], serous [2/43 (5%)], and clear cell [1/43 (2%)]. The endometrioid carcinomas were predominantly International Federation of Gynecology and Obstetrics grade 3 (27/43, 63%). The histotype distribution did not differ from that of control ECs ( P = 0.69), but the grade of the EC was higher ( P < 0.0005). Both nuclear grade and mitotic index were significantly higher in POLE ‐mutated ECs than in the comparison cohort. POLE ‐mutated ECs were associated with peritumoral lymphocytes and numerous tumour‐infiltrating lymphocytes. Lymphovascular invasion was present in 20 of 43 tumours. Adjuvant radiotherapy and adjuvant chemotherapy would be offered in up to 80% and 40% of patients, respectively, on the basis of stage, grade, lymphovascular invasion, and histotype. Conclusions: POLE ‐mutated ECs are typically of high grade, with prominent lymphocytic infiltration, but they are not sufficiently distinctive to allow accurate diagnosis based on routine haematoxylin and eosin staining. Even though POLE ‐mutated tumours are associated with an excellent prognosis, current guidelines for giving adjuvant treatment for EC result in most patients receiving adjuvant therapy.